简介:Duringthelastdecade,wehaveseentremendousprogressinthetherapyoflungcancer.DiscoveryofactionablemutationsinEGFRandtranslocationsinALKandROS1haveidentifiedsubsetsofpatientswithexcellenttumorresponsetooraltargetedagentswithmanageablesideeffects.Inthisreview,wehighlighttreatmentoptionsincludingcorrespondingclinicaltrialsforoncogenicalterationsaffectingthereceptortyrosinekinasesMET,FGFR,NTRK,RET,HER2,HER3,andHER4aswellascomponentsoftheRAS-RAF-MEKsignalingpathway.